Protein could lead to better TB vaccine

The current vaccine for tuberculosis uses a bovine version of the disease to protect humans who've contracted the illness. It provides some protection but is not entirely effective. However, researchers from the National Heart and Lung Institute at Imperial College London say they've identified a protein that elicits a stronger immune response in those with TB. The protein, called EspC, could be used to provide more better immunity than the currently available vaccine. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.